July 28, 2008. United BioSource Corporation (UBC) and CogState Ltd. are pleased to announce that they have entered into a strategic partnership to facilitate the use of cognitive testing within clinical trials for pharmaceutical and life sciences companies . Customers will be able to leverage CogState's scientific and software capabilities with UBC's global operations to support full scale clinical development programs.
Cognitive impairment is a defining feature of many psychiatric and neurological diseases including Alzheimer's disease, schizophrenia, Parkinson's disease, ADHD, depression and stroke. Consequently, improving cognition has become an important outcome for new treatment strategies in these conditions, increasing the need for sensitive measures, assays and analyses that can be used to guide decisions about cognition. Furthermore there is also a need for processes and systems to cost-effectively manage the use of cognitive assessments in multi-national clinical development programs... United BioSource Corporation's Press Release - CogState's Press Release -
